Glucagon-Like Peptide-1 Protects Against Cardiac Microvascular Injury in Diabetes via a cAMP/PKA/Rho-Dependent Mechanism
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Impaired cardiac microvascular function contributes to cardiovascular complications in diabetes. Glucagon-like peptide-1 (GLP-1) exhibits potential cardioprotective properties in addition to its glucose-lowering effect. This study was designed to evaluate the impact of GLP-1 on cardiac microvascular injury in diabetes and the underlying mechanism involved. Experimental diabetes was induced using streptozotocin in rats. Cohorts of diabetic rats received a 12-week treatment of vildagliptin (dipeptidyl peptidase-4 inhibitor) or exenatide (GLP-1 analog). Experimental diabetes attenuated cardiac function, glucose uptake, and microvascular barrier function, which were significantly improved by vildagliptin or exenatide treatment. Cardiac microvascular endothelial cells (CMECs) were isolated and cultured in normal or high glucose medium with or without GLP-1. GLP-1 decreased high-glucose–induced reactive oxygen species production and apoptotic index, as well as the levels of NADPH oxidase such as p47phox and gp91phox. Furthermore, cAMP/PKA (cAMP-dependent protein kinase activity) was increased and Rho-expression was decreased in high-glucose–induced CMECs after GLP-1 treatment. In conclusion, GLP-1 could protect the cardiac microvessels against oxidative stress, apoptosis, and the resultant microvascular barrier dysfunction in diabetes, which may contribute to the improvement of cardiac function and cardiac glucose metabolism in diabetes. The protective effects of GLP-1 are dependent on downstream inhibition of Rho through a cAMP/PKA-mediated pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These agents exert their anti-atherosclerotic effects through various mechanisms, including by improving blood lipid profiles,444 preserving endothelial integrity and regulating endothelial function,445 as well as modulating inflammatory processes.70”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [444]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“GLP-1 receptor (GLP-1R) is widely expressed in islet cells, kidney, lung, brain, and, interestingly, heart (6,7).”
BackgroundCoronary Microvascular Dysfunction
Camici, P. G., & Crea, F. (2007) · New England Journal of Medicine · doi:10.1056/nejmra061889 · Cited by 1,605
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428 · cited 1×
“Accumulating evidence has demonstrated that microvascular injury plays a very important role in the diabetic cardiovascular dysfunction (4,5).”
BackgroundCoronary Microvascular Dysfunction
Crea, F., Lanza, G. A., & Camici, P. G. (2014) · Springer eBooks · doi:10.1007/978-88-470-5367-0 · Cited by 1,287
The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism
Koo, S.-H., Flechner, L., Qi, L., Zhang, X., Screaton, R. A., Jeffries, S., Hedrick, S., Xu, W., Boussouar, F., Brindle, P., et al. (2005) · Nature · doi:10.1038/nature03967 · Cited by 995 · cited 1×
“Complete viral vectors were generated by homologous recombination with the AdEASY vector as described (27).”
MethodNyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680 · cited 1×
“Furthermore, a study of diabetic patients found that infusion of GLP-1 was associated with improved endothelial function (9).”
BackgroundGlucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Bose, A. K., Mocanu, M. M., Carr, R. D., Brand, C. L., & Yellon, D. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 638 · cited 1×
“For example, GLP-1 is capable of protecting the heart against ischemia/reperfusion injury (38).”
BackgroundThe Multiple Actions of GLP-1 on the Process of Glucose-Stimulated Insulin Secretion
MacDonald, P. E., El-kholy, W., Riedel, M. J., Salapatek, A. M. F., Light, P. E., & Wheeler, M. B. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s434 · Cited by 590 · cited 5×
“To assess the potential role of intact GLP-1, DPP-4 inhibitors such as vildagliptin and GLP-1 analog exenatide are used as a means of preventing its degradation.”
BackgroundInfluentialExenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
Lønborg, J., Vejlstrup, N., Kelbæk, H., Bøtker, H. E., Kim, W. Y., Mathiasen, A. B., Jørgensen, E., Helqvist, S., Saunamäki, K., Clemmensen, P., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr309 · Cited by 550 · cited 1×
“It has been shown that administration of GLP-1 at the time of reperfusion was effective in decreasing myocardial infarct size in patients with acute myocardial infarction (8).”
Background
Cited by
Items 101–181 of 181
Potential Protective Mechanism in the Cardiac Microvascular Injury
Li, X., Hou, J., Du, J., Feng, J., Yang, Y., Shen, Y., Chen, S., Feng, J., Yang, D., Li, D., et al. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11035 · Cited by 27
Baylan, U., Korn, A., Emmens, R. W., Schalkwijk, C. G., Niessen, H. W. M., Krijnen, P. A. J., & Şimşek, S. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13807 · Cited by 26
Zhang, L., Li, C., Zhu, Q., Li, N., & Zhou, H. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7388 · Cited by 29
GLP-1 Receptor Agonists and Coronary Arteries: From Mechanisms to Events
de Mortanges, A. P., Sinaci, E., Salvador, D., Bally, L., Muka, T., Wilhelm, M., & Bano, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.856111 · Cited by 26
Lv, Y., Tang, L., Wei, J.-K., Xu, X., Gu, W., Fu, L., Zhang, L., & Du, L. (2013) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00179.2013 · Cited by 25
“5 normalized to -SMA per field were averaged for data analysis (35).”
Methodvan den Brom, C. E., Bulte, C. S. E., Loer, S. A., Bouwman, R. A., & Boer, C. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-42 · Cited by 25
“Moreover, exenatide increased myocardial glucose uptake in healthy [140] and insulin resistant dilated cardiomyopathy [141] mice, whereas it did not alter myocardial glucose uptake in type 2 diabetic patients [142].”
BackgroundZhang, X., Ma, S., Zhang, R., Li, S., Zhu, D., Han, D. H., Li, X., Li, C., Yan, W., Sun, D., et al. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv137 · Cited by 25
Self-citationSharif, M., Baek, Y., Naveed, A., Stalin, N., Kang, M.-I., Park, S., Soliman, M., & Cho, K. (2021) · Journal of Virology · doi:10.1128/jvi.00051-21 · Cited by 25
Vildagliptin protects endothelial cells against high glucose-induced damage
Zhang, M., Jin, X., Zhang, Z., Li, B., & Yang, G. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.09.148 · Cited by 22
Durak, A. T., Akkuş, E., Canpolat, A. G., Tuncay, E., Çorapçıoğlu, D., & Turan, B. (2021) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13590 · Cited by 23
New insights into the roles of Irisin in diabetic cardiomyopathy and vascular diseases
Zhang, T., Qian, Y., Huang, W., Feng, J., & Liu, H. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116631 · Cited by 25
Wu, Y., Zou, Y., Song, C., Cao, K., Cai, K., Chen, S., Zhang, Z., Geng, D., Zhang, N., Feng, H., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117093 · Cited by 22
Lin28a protects against diabetic cardiomyopathy via the PKA/ROCK2 pathway
Sun, S., Zhang, M., Lin, J. M., Hu, J., Zhang, R., Li, C., Wei, T., Sun, D., Wei, J., & Wang, H. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.11.065 · Cited by 20
“ROCK1 and ROCK2 are Rho-associated kinases activated by the small GTP-binding protein RhoA [12].”
BackgroundSelf-citationTai, H., Wang, M., Yue-ping, Z., Li, L., Dong, Q.-Y., Liu, X., & Jin-song, K. (2016) · Medicine · doi:10.1097/md.0000000000004541 · Cited by 22
“Glucagon likepeptide-1 (GLP-1), an incretin hormone, can prevent high-glucose-induced oxidative stress in cardiacmicrovascular endothelial cells, possibly through inhibition of activation of the Rho/ROCK pathway.([11]) By decreasing the GLP-1 level, dipeptydil-peptidase-4 (DPP-4) inhibitors have become the new breakth…”
BackgroundGuo, Z., Qi, W., Yu, Y.-X., Du, S., Wu, J., & Liu, J. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-29 · Cited by 20
Król, M., Kupnicka, P., Żychowska, J., Kapczuk, P., Szućko-Kociuba, I., Prajwos, E., & Chlubek, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146777 · Cited by 19
“In cardiac microvascular endothelial cells (CMECs), GLP-1 RA reduced ROS production, apoptosis rates, and NADPH oxidase components (p47(phox) and gp91(phox)) under high-glucose conditions in vitro [108].”
InfluentialAKAP150 mobilizes cPKC-dependent cardiac glucotoxicity
Zeng, C., Wang, J., Li, N., Shen, M., Wang, D., Yu, Q., & Wang, H. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00175.2014 · Cited by 19
Self-citationXu, S., Li, J., Zhai, M., Yao, X., Liu, H., Deng, T., Cai, H., Zhang, W., Zhang, W., Lou, J.-N., et al. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.03.068 · Cited by 18
Glucagon-like peptide 1 reverses myocardial hypertrophy through cAMP/PKA/RhoA/ROCK2 signaling
Fan, S., Xiong, Q., Zhang, X., Zhang, L., & Shi, Y. (2020) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmaa038 · Cited by 18
The role of A-kinase anchoring proteins in cardiac oxidative stress
Diviani, D., Osman, H., Delaunay, M., & Kaiser, S. (2019) · Biochemical Society Transactions · doi:10.1042/bst20190228 · Cited by 16
Abu-Nejim, H., & Becker, R. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01350-7 · Cited by 16
“In each group micro-vascular blood flow velocity, blood volume, and myocardial perfusion were increased and improved, respectively, to variable degrees [67].”
Jabir, M. S., Al-Shammari, A. M., Ali, Z. O., Albukhaty, S., Sulaiman, G. M., Jawad, S. F., Hamzah, S. S., Syed, A., Elgorban, A. M., Eswaramoorthy, R., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-42299-4 · Cited by 18
Sun, L., Wang, C., Dai, Y., Chu, Y., Han, J. D. J., Zhou, J., Cai, X., Huang, W., & Qian, H. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.10.028 · Cited by 15
Self-citationMa, X., Zhang, J., Wu, Z., & Wang, X. (2020) · Journal of Receptors and Signal Transduction · doi:10.1080/10799893.2020.1817076 · Cited by 19
Self-citationImpact of glucagon-like peptide-1 on myocardial glucose metabolism revisited
Hansen, J., Brock, B., Bøtker, H. E., GJEDDE, A. H., Rungby, J., & Gejl, M. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9286-8 · Cited by 16
Ma, Y., Liu, X., Bi, Y., Wang, T., Chen, C. Y., Wang, Y., Han, D. H., & Cao, F. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.849175 · Cited by 14
Self-citationPotential cardioprotective action of GLP-1: from bench to bedside
Aronis, K. N., Tsoukas, M. A., & Mantzoros, C. S. (2014) · Metabolism · doi:10.1016/j.metabol.2014.05.009 · Cited by 14
Zhou, X., Wang, D., Zhang, Y., Zhang, J., Xiang, D., & Wang, H. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0004-7 · Cited by 14
Self-citationThe Role of Platelets in Diabetes Mellitus
Santilli, F., Simeone, P., & Liani, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813456-6.00027-8 · Cited by 17
Li, B., Luo, Y. R., Zhang, Q., Fu, S., Chen, Y. D., Tian, J., & Guo, Y. (2021) · Vascular Pharmacology · doi:10.1016/j.vph.2021.106854 · Cited by 14
Liraglutide Effect on Ventricular Transient Outward K + Channel and Connexin-43 Protein Expression
Ramadan, N. M., Malek, H. A., Rahman, K. A., El-Kholy, E., Shaalan, D., & Elkashef, W. F. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1162-8196 · Cited by 13
Exercise alleviates cardiac remodelling in diabetic cardiomyopathy via the miR-486a-5p-Mst1 pathway.
Sun, D., Wang, H., Su, Y., Lin, J. M., Zhang, M., Man, W., Song, X., Zhang, L., Guo, B., Hao, K., et al. (2021) · PubMed Central · doi:10.22038/ijbms.2020.50808.11564 · Cited by 14
Self-citationProtective Role of Glucagon-Like Peptide-1 Against High-Glucose-Induced Endothelial Oxidative Damage
Guo, L., Qiao, Y., Zhang, L., & Pan, Q. (2015) · Medicine · doi:10.1097/md.0000000000002055 · Cited by 11
“D-glucose, GLP-1(7-36), MTT, and collagenase I were purchased from Sigma Aldrich (Shanghai, China).”
MethodThe Gut–Brain-Axis as a Target to Treat Stress-Induced Obesity
Lee, C. Y., & Abizaid, A. B. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00117 · Cited by 14
Kadowaki, S., Siraj, M. A., Chen, W., Wang, J., Parker, M., Nagy, A., Fan, C. S., Runeckles, K., Li, J., Kobayashi, J., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.027163 · Cited by 11
“22 Here we sought to elucidate the effects of exenatide in a juvenile pig DCD heart model using a pediatric-specific EVHP.”
Shen, C., Xu, L., Han, S., Dong, Z., Zhao, X., Wang, S., Qian, S., Li, B., Ma, X., Wang, P., et al. (2017) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2017-104780 · Cited by 10
Self-citationGut Molecules in Cardiometabolic Diseases: The Mechanisms behind the Story
Inceu, A.-I., Neag, M. A., Craciun, A. E., & Buzoianu, A. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043385 · Cited by 11
“GLP-1 infusion in cardiac microvascular endothelial cells cultured in high glucose conditions decreased oxidative stress generation and reduced the apoptosis index, improving vascular dysfunction in a cAMP/PKA-dependent manner [72].”
BackgroundEid, R. A., Zaki, M. S. A., Eldeen, M. A., Alshehri, M. M., Shati, A. A., & El-kott, A. F. (2020) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13299 · Cited by 10
Liraglutide prevents fast weight gain and β-cell dysfunction in male catch-up growth rats
Zheng, J., Chen, T., Zhu, Y. Y., Li, H., Deng, X., Wang, Q., Zhang, J., & Chen, L. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370214567614 · Cited by 9
Seimon, R. V., Espinoza, D., Finer, N., James, W. P. T., Legler, U. F., Coutinho, W. F., Sharma, A. M., Gaal, L. V., Maggioni, A. P., Sweeting, A., et al. (2014) · International Journal of Obesity · doi:10.1038/ijo.2014.211 · Cited by 10
Huang, J.-H., Chen, Y., Lin, Y., Lin, Y.-K., Chen, Y., & Chen, Y. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0564-3 · Cited by 9
Turan, B., Durak, A. T., Olğar, Y., & Tuncay, E. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04474-5 · Cited by 9
Lin, J., Zhang, X., Ge, W., Duan, Y., Zhang, X., Zhang, Y., Dai, X., Jiang, M., Zhang, X., Zhang, J., et al. (2025) · Diabetes · doi:10.2337/db24-0543 · Cited by 7
Self-citationGe, G., Dou, H., Yang, S.-S., Ma, J., Cheng, W., Qiao, Z., Hou, Y., & Fang, W. (2015) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/s1995-7645(14)60191-7 · Cited by 7
Yang, Y., Yang, Y., Wang, X., Du, J., Hou, J., Feng, J., Tian, Y., He, L., Li, X., & Pei, H. (2016) · Journal of International Medical Research · doi:10.1177/0300060516658984 · Cited by 7
“diabetes-induced cardiac microvascular injury provided by intestine-derived glucagon-like peptide 1.(42) Notably, the renin– angiotensin–aldosterone system closely links the kidney and heart, and significantly affects blood pressure and cardiac remodelling.”
BackgroundEfficacy of glucagon-like peptide-1 mimetics for neural regeneration
Sango, K., & Utsunomiya, K. (2015) · Neural Regeneration Research · doi:10.4103/1673-5374.169611 · Cited by 7
Tanashat, M., Al‐Ajlouni, Y. A., Abuelazm, M., Altobaishat, O., Manasrah, A., Turkmani, M. M., Khan, U., & Abouzid, M. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00726-z · Cited by 9
Liu, Y., Tseng, Y., Wu, Y.-H., Tong, L., Tsai, S., Huang, S., Wu, B., Lo, S., Chen, I.-C., Dai, Z., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177106 · Cited by 7
Wieland, F. C., Sthijns, M. M. J. P. E., Geuens, T., van Blitterswijk, C., & LaPointe, V. L. S. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.729057 · Cited by 5
Asemi, Z., Salami, R., Salami, M., Mafi, A., Aarabi, M. H., & Vakili, O. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220829102020 · Cited by 7
Carabelli, A., Canu, M., de Fondaumière, M., Debiossat, M., Leenhardt, J., Broisat, A., Ghezzi, C., Vanzetto, G., Fagret, D., Barone‐Rochette, G., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05511-z · Cited by 5
GLP‐1: A Prospective Guardian for Comprehensive Myocardial Perfusion
Li, Z., Yu, Y., Li, J., Jiang, X., Chen, J., Ye, N., Wu, B., Sun, Y., & Sun, G. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70004 · Cited by 5
“This potential mechanism may be due to the inhibition of the Rho/ROCK pathway, which mediates oxidative stress damage [46].”
Chinese Society of Cardiology, C. M. A., & Editorial Board of Chinese Journal of Cardiology (2023) · Cardiology Discovery · doi:10.1097/cd9.0000000000000104 · Cited by 3
Mahmoud, A. K., Awad, K., Sheashaa, H., Kandil, O., Farina, J. M., Ibrahim, R., Abdelnabi, M., Allam, M., Mital, R., Shipman, J., et al. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag051 · Cited by 3
The therapeutic approach to cardiovascular–kidney–metabolic syndrome
Rangaswami, J., Lo, K. B., & Ndumele, C. E. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01109-6 · Cited by 4
Chun-peng, Z., Tian, C., & Xue, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33308 · Cited by 4
“Inflammatory factors such as MCP-1 and VCAM-1 are involved in the pathophysiological process of DCM [100,101].”
BackgroundVascular failure and recent anti-diabetic drugs
Oyama, J., & Node, K. (2017) · Vascular Failure · doi:10.30548/vascfail.1.1_2 · Cited by 3
Abdel‐Hamid, A. A. M., & Firgany, A. E. L. (2019) · Acta Histochemica · doi:10.1016/j.acthis.2019.151499 · Cited by 4
Fujishiro, M., Ishihara, H., Ogawa, K., Murase, T., Nakamura, T., Watanabe, K., Sakoda, H., Ono, H., Yamamotoya, T., Nakatsu, Y., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9081052 · Cited by 3
“Interestingly, this study also revealed increases in both incretin and its mimetics, due to the use of GLP1RAs or DPP4is, to be related to low XOR activity, an observation consistent with accumulating evidence that incretins induce anti-inflammatory effects by downregulating ROS production and NF-κB activation in vasc…”
ResultPhloridzin's Diabetic Wound Healing Potential through DPP-4 Enzyme Inhibition: A Review Article
Sharma, K., Ramachandran, V., Sharma, A., Mohanasundaram, T., & Magesh, H. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998291941240416053855 · Cited by 3
An, N., Yu, L., Hu, Y., Feng, W., Shi, S., Chen, H., & Mao, Y. (2018) · Journal of Ocean University of China · doi:10.1007/s11802-019-3998-z · Cited by 3
Wang, D., Zhang, R., Zhou, X., Ma, S., Qin, X., Wang, J., Gao, H., Wang, Q., Li, C., Chen, Y., et al. (2015) · European Heart Journal Supplements · doi:10.1093/eurheartj/suv050 · Cited by 3
Self-citationGLP-1 and GIP in Type 1 Diabetes Therapy: A Time for Reappraisal?
Piras, G., Brasili, S., Demontis, D., Sala, L. D., Cocchiara, F., Maggi, D. C., & Arecco, A. (2026) · Diabetology · doi:10.3390/diabetology7030050 · Cited by 2
A hypothesis: Glucagon-like peptide-1 may play a protective role in diabetic cardiomyopathy
Fan, Z., Yang, C., & Yang, J. M. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.06.108 · Cited by 2
Abdelnabi, M. H., Chaisrimaneepan, N., Castillo‐Rodriguez, C., Eshak, N., Sullivan, M. M., Ibrahim, R., Pham, H. N., Farina, J., Ayoub, C., Nagaraja, V., et al. (2025) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-025-01124-z · Cited by 1
Endothelial dysfunction as a driver of microvascular injury in diabetic cardiomyopathy
Siriwattanawong, P., Justin, R., Gamachchige, P. R., Zhou, D., & Chen, T. (2025) · Vessel Plus · doi:10.20517/2574-1209.2025.75 · Cited by 1
Shu, Q., Lin, Y., Su, W., Peng, H., & Wang, X. Y. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117789 · Cited by 1
Bao, W., Xu, J., Nian, W., Pang, P., Wu, W., Huang, Z., Hu, L., Zhang, Q., Pan, W., Gao, X., et al. (2026) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.126.324797 · Cited by 1
Is There a Role for the Incretin System in Blood Pressure Regulation?
Rao, A., & Nistala, R. (2014) · Current Hypertension Reports · doi:10.1007/s11906-013-0417-5 · Cited by 1
Liu, Z., Wang, H.-T., Tang, J. P., & Qin, Z. (2017) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.1673-4254.2017.10.12 · Cited by 1
Self-citationMst1-Nrf2 regulates myocardial injury in type 2 diabetic mice through autophagyPreprint
Wang, J., Li, G., Wang, N., Wang, L., Li, J., & Xiao, W. (2022) · Research Square · doi:10.21203/rs.3.rs-1267119/v1
“Nrf2 is a "switch" that switches on endogenous antioxidant responses, activating genes that reduce oxidative stress [9,10] .”
BackgroundProgress in Drug Therapy of Coronary Microvascular Endothelial Dysfunction
张, 梦. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.1291171
Zhang, X., Duan, Y., Zhang, X., Jiang, M., Man, W., Zhang, Y., Wu, D., Zhang, J., Song, X., Li, C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26592239
Self-citationZhang, X., Duan, Y., Zhang, X., Jiang, M., Man, W., Zhang, Y., Wu, D., Zhang, J., Song, X., Li, C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26592242
Self-citationZhang, X., Duan, Y., Zhang, X., Jiang, M., Man, W., Zhang, Y., Wu, D., Zhang, J., Song, X., Li, C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26592236
Self-citationLücht, C. L.-M. (2026) · University of Regensburg Publication Server (University of Regensburg) · doi:10.5283/epub.78420
KONDO, M., & Kondo, M. (2022) · Institutional Repositories DataBase (IRDB) · doi:10.15111/00003019
Dépôts de graisse ectopique : étude de leur développement et de leur modulation
Abdesselam, I. (2016) · theses.fr (ABES) · doi:10.70675/1f016024z175cz4b35z8034za3b418cfe9c3 · Cited by 1
Arecco, A., Piras, G., Cocchiara, F., Maggi, D. C., & Puddu, A. (2026) · Diabetology · doi:10.3390/diabetology7100187
Advances in weight-loss-independent cardiovascular protective mechanisms of GLP-1 receptor agonists
Ma, J., Feng, X., Xu, W., & Lyu, J. (2026) · Peptides · doi:10.1016/j.peptides.2026.171519
Metadata
- Authors
- Wang, D., Luo, P., Wang, Y., Li, W., Wang, C., Sun, D., Zhang, R., Su, T., Ma, X., Zeng, C., Wang, H., Ren, J., & Cao, F.
- Affiliations
- Xijing Hospital (CN)
- University of Wyoming (US)
- Corresponding author
- Cao, Feng
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2013-04-16
- Volume
- 62
- Issue
- 5
- Pages
- 1697-1708
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3636622
- OpenAlex
- W2117213923
- Cited by
- 179
- References
- 54
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 12 · 2023: 6 · 2022: 13 · 2021: 11 · 2020: 11 · 2019: 15 · 2018: 9 · 2017: 21 · 2016: 16 · 2015: 21 · 2014: 22 · 2013: 7
- FWCI
- 17.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Keywords
- glucagon-like peptide-1, vildagliptin, exenatide, DPP-4 inhibitors, cardiac microvascular endothelial cells, cAMP/PKA signaling, Rho, oxidative stress, apoptosis, NADPH oxidase, cardiac glucose metabolism, streptozotocin-induced diabetes
- MeSH terms
- Exenatide, Cyclic AMP, Animals, Cardiotonic Agents, Cells, Cultured, Diabetic Angiopathies, Disease Models, Animal, Endothelium, Vascular, Heart Ventricles, Hyperglycemia, Hypoglycemic Agents, Male, Peptides, Random Allocation, Venoms, Second Messenger Systems, Rats, Sprague-Dawley, Oxidative Stress, rho GTP-Binding Proteins, Rats, Glucagon-Like Peptide 1, AMP-Activated Protein Kinases, Microvessels, Diabetic Cardiomyopathies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.